Company intelligence / Profile preview
AbBC Therapies
Bolton, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Preclinical data demonstrates high cytotoxicity in vitro and tumor regression in vivo across multiple tumor models; GrB-Fc-IT4 advancing to Phase 1 safety/tolerability trial in Fn14+ tumors Q2 2026; GrB-Fc-VEGF preclinical data expected Q1 2025
- Therapeutic areas
- OncologyOphthalmology
- Modalities
- Antibody-drug conjugateImmunotoxinFusion protein
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
WuXi Biologics (GMP, manufacturing and scale-up)Cromos Pharma (advisory)
Beyond the preview
Go deeper on AbBC Therapies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AbBC Therapies.